Table 3.
B-cell non-Hodgkin’s lymphoma subtypes
| N total | Chronic lymphocytic leukemia/small cell lymphoma | Lymphoplasmocytic lymphoma (Waldenstrom macroglobulinaemia) |
Marginal zone lymphoma | Follicular lymphoma | Mantle cell lymphoma | Diffuse large B-cell lymphoma | Burkitt lymphoma | ||||||||
| n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | ||
| Bionaïve | 184 | 28 | 15.2 (9.2 to 23.2) |
4 | 2.2 (0.4 to 6.8) |
1 | 0.5 (0 to 4.1) |
33 | 17.9 (11.3 to 26.6) |
5 | 2.7 (0.6 to 7.6) |
113 | 61.4 (51.5 to 70.8) |
0 | 0 (0 to 3.0) |
| TNFi | 151 | 26 | 17.2 (10.1 to 26.8) |
6 | 4.0 (1.1 to 10.1) |
10 | 6.6 (2.6 to 13.6) |
34 | 22.5 (14.3 to 32.6) |
0 | 0 (0 to 3.6) |
75 | 49.7 (38.6 to 60.8) |
0 | 0 (0 to 3.6) |
| RTX | 5 | 1 | 20.0 (1.4 to 79.6) |
1 | 20.0 (1.4 to 79.6) |
0 | 0 (0 to 62.9) |
1 | 20.0 (1.4 to 79.6) |
0 | 0 (0 to 62.9) |
2 | 40.0 (2.8 to 90.6) |
0 | 0 (0 to 62.9) |
| TOC | 5 | 2 | 40.0 (2.8 to 90.6) |
0 | 0 (0 to 62.9) |
0 | 0 (0 to 62.9) |
0 | 0 (0 to 62.9) |
0 | 0 (0 to 62.9) |
3 | 60.0 (9.4 to 97.3) |
0 | 0 (0 to 62.9) |
| ABA | 3 | 0 | 0 (0 to 80.7) |
0 | 0 (0 to 80.7) |
0 | 0 (0 to 80.7) |
2 | 66.7 (5.0 to 99.8) |
0 | 0 (0 to 80.7) |
1 | 33.3 (0.2 to 95.0) |
0 | 0 (0 to 80.7) |
| RA total | 348 | 57 | 16.4 (11.6 to 22.2) |
11 | 3.2 (1.3 to 6.4) |
11 | 3.2 (1.3 to 6.4) |
70 | 20.1 (14.7 to 26.4) |
5 | 1.4 (0.3 to 4.0) |
194 | 55.8 (48.4 to 62.9) |
0 | 0 (0 to 1.6) |
| General population |
28 747 | 11 019 | 38.3 (37.6 to 39.1) |
1859 | 6.5 (6.1 to 6.9) |
950 | 3.3 (3.0 to 3.6) |
4881 | 17.0 (16.4 to 17.6) |
1012 | 3.5 (3.2 to 3.8) |
8538 | 29.7 (29.0 to 30.4) |
488 | 1.7 (1.5 to 1.9) |
ABA, abatacept; RA, rheumatoid arthritis; RTX, rituximab; TNFi, tumour necrosis factor inhibitor; TOC, tocilizumab.